Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 11 Jun 2012 |
| Zealand Pharma to present at upcoming Global Healthcare investor conferences in the US | 29 May 2012 |
| Zealand Pharma A/S Announcement of transactions in the company’s shares and related securities by executives and their related parties | 9 May 2012 |
| Zealand Pharma signs licensing agreement with Abbott for the further clinical development and commercialization of AP214 (ZP1480) for prevention of acute kidney injury | 3 May 2012 |
| Zealand Pharma A/S – Interim report for Q1 2012 (un-audited) | 25 Apr 2012 |